CareDx, Inc (CDNA)
CDNA Stock Price Chart
Explore CareDx, Inc interactive price chart. Choose custom timeframes to analyze CDNA price movements and trends.
CDNA Company Profile
Discover essential business fundamentals and corporate details for CareDx, Inc (CDNA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Medical - Diagnostics & Research
IPO Date
17 Jul 2014
Employees
644.00
Website
https://www.caredx.comCEO
John Walter Hanna Jr.
Description
CareDx, Inc. is a global innovator specializing in the discovery, development, and commercialization of diagnostic and management tools designed for transplant recipients and their healthcare providers. The company's extensive portfolio features a range of specialized diagnostic solutions for organ monitoring, including: AlloSure Kidney, AlloSure Heart, and AlloSure Lung: Advanced tests employing donor-derived cell-free DNA (dd-cfDNA) technology to assess the health of kidney, heart, and lung transplants, respectively. AlloMap Heart: A gene expression-based solution specifically for heart transplant patients. AlloSeq cfDNA: A broader surveillance tool to measure dd-cfDNA levels in the blood. CareDx also provides cutting-edge human leukocyte antigen (HLA) typing technologies, such as TruSight HLA, an NGS-based high-resolution typing solution; Olerup SSP, which uses sequence-specific primer technology for HLA allele typing; QTYPE for precise HLA typing; and AlloSeq Tx, another high-resolution HLA typing offering. For stem cell transplant recipients, the company offers AlloSeq HCT for chimerism testing. Beyond diagnostics, CareDx develops vital software and digital platforms to streamline transplant patient management. These include Ottr, a dedicated transplant patient management software; XynQAPI, focused on transplant quality tracking and waitlist management; and AlloCare, a mobile application serving as a patient-centric resource for those who have undergone transplantation. The company distributes its products directly to clients, as well as through a network of third-party distributors and sub-distributors. CareDx has forged significant partnerships, including a licensing agreement with Illumina, Inc. for the distribution, development, and commercialization of next-generation sequencing (NGS) products and technologies. Additionally, it collaborates with Cibiltech SAS to commercialize iBox, a software designed for the predictive analysis of kidney allograft loss post-transplantation. Founded in 1998, the company was initially known as XDx, Inc. before rebranding to CareDx, Inc. in March 2014. Its headquarters are located in South San Francisco, California.
CDNA Financial Timeline
Browse a chronological timeline of CareDx, Inc corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Jul 2026
EPS estimate is $0.22, while revenue estimate is $113.85m.
Earnings released on 28 Apr 2026
EPS came in at $0.34 surpassing the estimated $0.11 by +209.09%, while revenue for the quarter reached $117.70m , beating expectations by +15.36%.
Earnings released on 24 Feb 2026
EPS came in at $0.12 surpassing the estimated $0.02 by +503.02%, while revenue for the quarter reached $108.39m , beating expectations by +4.95%.
Earnings released on 4 Nov 2025
EPS came in at $0.28 surpassing the estimated $0.13 by +115.38%, while revenue for the quarter reached $100.06m , missing expectations by -2.63%.
Earnings released on 6 Aug 2025
EPS came in at $0.10 falling short of the estimated $0.12 by -16.67%, while revenue for the quarter reached $86.68m , missing expectations by -9.00%.
Earnings released on 30 Apr 2025
EPS came in at $0.09 surpassing the estimated $0.06 by +50.00%, while revenue for the quarter reached $84.69m , beating expectations by +0.18%.
Earnings released on 26 Feb 2025
EPS came in at $0.18 surpassing the estimated $0.05 by +260.00%, while revenue for the quarter reached $86.58m , beating expectations by +2.39%.
Earnings released on 4 Nov 2024
EPS came in at $0.14 surpassing the estimated $0.01 by +1.30k%, while revenue for the quarter reached $82.88m , beating expectations by +0.88%.
Earnings released on 31 Jul 2024
EPS came in at $0.25 surpassing the estimated -$0.13 by +292.31%, while revenue for the quarter reached $92.27m , beating expectations by +15.99%.
Earnings released on 9 May 2024
EPS came in at -$0.03 surpassing the estimated -$0.19 by +84.21%, while revenue for the quarter reached $72.05m , beating expectations by +14.11%.
Earnings released on 28 Feb 2024
EPS came in at -$0.17 surpassing the estimated -$0.24 by +29.17%, while revenue for the quarter reached $65.57m , beating expectations by +3.01%.
Earnings released on 8 Nov 2023
EPS came in at -$0.18 surpassing the estimated -$0.38 by +52.63%, while revenue for the quarter reached $67.19m , beating expectations by +8.90%.
Earnings released on 8 Aug 2023
EPS came in at -$0.18 surpassing the estimated -$0.42 by +57.14%, while revenue for the quarter reached $70.30m , beating expectations by +13.83%.
Earnings released on 10 May 2023
EPS came in at -$0.11 falling short of the estimated -$0.07 by -57.14%, while revenue for the quarter reached $77.26m , missing expectations by -4.26%.
Earnings released on 27 Feb 2023
EPS came in at -$0.07 falling short of the estimated -$0.06 by -16.67%, while revenue for the quarter reached $82.38m , beating expectations by +0.88%.
Earnings released on 3 Nov 2022
EPS came in at -$0.06 surpassing the estimated -$0.14 by +57.14%, while revenue for the quarter reached $79.36m , missing expectations by -3.95%.
Earnings released on 4 Aug 2022
EPS came in at -$0.13 falling short of the estimated -$0.08 by -62.50%, while revenue for the quarter reached $80.63m , missing expectations by -1.49%.
Earnings released on 5 May 2022
EPS came in at -$0.13 falling short of the estimated -$0.05 by -160.00%, while revenue for the quarter reached $79.42m , beating expectations by +0.62%.
Earnings released on 24 Feb 2022
EPS came in at -$0.03 falling short of the estimated -$0.01 by -192.40%, while revenue for the quarter reached $79.22m , beating expectations by +2.89%.
Earnings released on 28 Oct 2021
EPS came in at $0.07 surpassing the estimated $0.01 by +483.33%, while revenue for the quarter reached $75.59m , beating expectations by +2.83%.
Earnings released on 29 Jul 2021
EPS came in at $0.11 surpassing the estimated $0.05 by +120.00%, while revenue for the quarter reached $74.19m , beating expectations by +9.49%.
CDNA Stock Performance
Access detailed CDNA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
